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Abstract Asthma and chronic obstructive pulmonary
disease (COPD) are pulmonary diseases that are charac-
terized by inﬂammatory cell inﬁltration, cytokine
production, and airway hyper-reactivity. Most of the
effector cells responsible for these pathologies reside in the
lungs. One of the most direct ways to deliver drugs to the
target cells is via the trachea. In a pre-clinical setting, this
can be achieved via intratracheal (IT), intranasal (IN), or
aerosol delivery in the desired animal model. In this study,
we pioneered the aerosol delivery of a nanosuspension
formulation in a rodent model. The efﬁciency of different
dosing techniques and formulations to target the lungs were
compared, and ﬂuticasone was used as the model com-
pound. For the aerosol particle size determination, a ten-
stage cascade impactor was used. The mass median aero-
dynamic diameter (MMAD) was calculated based on the
percent cumulative accumulation at each stage. Formula-
tions with different particle size of ﬂuticasone were made
for evaluation. The compatibility of regular ﬂuticasone
suspension and nanosuspension for aerosol delivery was
also investigated. The in vivo studies were conducted on
mice with optimized setting. It was found that the aerosol
delivery of ﬂuticasone with nanosuspension was as
efﬁcient as intranasal (IN) dosing, and was able to achieve
dose dependent lung deposition.
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Introduction
Pulmonary diseases, such as chronic obstructive pulmonary
disease (COPD) and asthma are complex human airway
diseases which affect millions of people worldwide. These
human airway diseases are characterized by a strong lung
inﬂammatory component with inﬂammatory cell inﬁltra-
tion, cytokine production, and airway hyper-reactivity.
Pulmonary disease populations are continuously
increasing worldwide. More than 6% of the total US pop-
ulation suffered from asthma in 2004, up from a little over
3% in 1980. For these patients, glucocorticoids are often
prescribed as ﬁrst-line therapy to control symptoms,
improve lung function, and reduce morbidity and mortality
[1]. A treatment option for severe asthmatics is continuous
or near continuous oral steroids (prednisolone). However,
long-term use of high-dose ICS therapy has the potential
to cause undesirable side effects. Side effects such
as impaired growth in children, decreased bone mineral
density, cataracts, skin thinning and bruising, glucose
metabolism, and other hypothalamic–pituitary–adrenal-
axis (HPA-axis) suppression effects are widely reported
[1–5]. Multiple studies have demonstrated that the side
effects of glucocorticoid therapy for human airway dis-
eases are related to the systemic exposure of the drugs.
More importantly, receptors responsible for efﬁcacy in the
lungs are also expressed in systemic tissues which are
P.-C. Chiang (&)  J. W. Alsup  Y. Lai  Y. Hu 
B. R. Heyde  D. Tung (&)
Global Research and Development, Pharmaceutical Research
and Development, St. Louis Laboratories, Pﬁzer Inc,
700 Chesterﬁeld parkway N. T2F, Chesterﬁeld, MO, USA
e-mail: Po-chang.chiang@pﬁzer.com
D. Tung
e-mail: Dvaid.Tung@pﬁzer.com
123
Nanoscale Res Lett (2009) 4:254–261
DOI 10.1007/s11671-008-9234-1responsible for systemic side effects [6–9]. Due to the
above ﬁndings, pulmonary targeting such as inhaled
delivery is believed to provide an advantage over systemic
administration, where the same degree of efﬁcacy can be
achieved with lower systemic exposure.
Aerosol pulmonary drug delivery is the preferred route
of administration in the treatment of respiratory disease
[10, 11]. Direct pulmonary delivery in humans is achieved
using an aerosol generated by either an inhaler or nebu-
lizer. The pharmaceutical industry is constantly seeking
better and safer treatments for the pulmonary diseases. A
major challenge in the identiﬁcation of pulmonary drug
candidate is demonstrating pre-clinical efﬁcacy in appro-
priate animal models with good translatability to humans.
In order to predict accurately the efﬁcacy, delivery, dis-
tribution, and PK of an inhaled drug, it is necessary to
simulate the characteristics of the drug aerosol in pre-
clinical models. Intranasal and intratracheal delivery of test
compounds are often used to deliver drugs directly to the
lungs of experimental animals. However, the above meth-
ods are not practical in the clinical setting where an inhaler
or nebulizer is used. Such a disconnect makes predicting
PK/PD and efﬁcacious dose in humans very difﬁcult. A
better pre-clinical modeling of drug delivery is necessary to
obtain more accurate estimation of drug efﬁcacy. In this
study, aerosol delivery in an animal model was investigated
and ﬂuticasone propionate was used as a model compound.
Fluticasone is a highly potent anti-inﬂammatory drug and
is the most commonly prescribed inhaled glucocortioid. A
nanosuspension formulation (D50 0.2 lm) was evaluated
against regular suspension (D50 1.6 lm) for aerosol
delivery.
Nanosuspension has been widely used for drug delivery
[12–16]. There are three key advantages of using nano-
suspension formulations instead of solution formulations
for pulmonary aerosol delivery. First, unlike solution for-
mulations, nanosuspension formulations can be prepared
without using large amount of organic co-solvents, thereby
reducing the in vivo interference and potential toxicologi-
cal effects caused by the co-solvents. Second, contrary to
solution formations, the concentration of nanosuspension is
not limited by solubility in the vehicle, thus, a wider dose
range can be achieved. Finally, nanosuspension formula-
tions provide superior content uniformity which results in
greater conﬁdence of delivery and reproducibility. More-
over, this mode of delivery can result in penetration of deep
lung and smaller airways, leading to a more even drug
distribution and resulting in a more accurate modeling of
the drug distribution and efﬁcacy.
In addition to the advantages conferred by nanosus-
pension formulations, there are several reasons to choose
aerosol delivery as well. Importantly, aerosol delivery has
been widely used and evaluated for pulmonary drug
delivery in humans. We believe combining nanosuspension
and aerosol in the pre-clinical setting will enable better and
more consistent results can be generated. This advantage
should allow us establish a more accurate modeling of the
drug distribution and the resulting efﬁcacy. Despite the
advantages of aerosol delivery, many factors can affect the
outcome. Particle size, dosing system ﬂow rate, charac-
teristics of the nebulizer, and drug solution concentration
can often affect the characteristics of the aerosol and the
delivery efﬁciency. In general, particles \5 lm are con-
sidered suitable for inhaled drug delivery, and have a
higher probability of being deposited in the airways of the
lungs [17]. Despite these general understandings, conven-
tional inhalers are found to be inefﬁcient and highly
variable in delivering the desired dose to patients [18].
Many factors have contributed to the above ﬁndings.
Devices such as pressurized and ultrasonic nebulizers
produce widely dispersed particle sizes and operate con-
tinuously, producing aerosol even when patients are not
inhaling. This results in large transfer losses and poor lung
deposition efﬁciencies [19] with the lung deposition being
between 6 and 10% of the administered dose [20]. Despite
the relatively low percent of deposition, the wide spread
distribution of the particles in the lung results in equal or
higher efﬁcacy as compared to intratracheal or intranasal
methods [21, 22]. In this study, we pioneer the pre-clinical
use of nanosuspension for aerosol delivery. The effects of
various parameters are optimized to generate an aerosol
capable of delivering a suitable dosage to support pre-
clinical studies in rodents. Lung deposition, plasma
exposure, impact on particle size, and delivery techniques
are evaluated.
Materials and Methods
Materials
Fluticasone propionate was purchased from Sequoia
Research Products (Oxford, UK). HPLC grade acetonitrile
was obtained from Burdick and Jackson (Muskegon, MI),
and reagent grade formic acid, sodium hydroxide obtained
from EM Science (Gibbstown. N J). The HPLC system
used for formulation potency check was an Agilent HP
1100 HPLC equipped with a diode array (DAD) and a
variable wavelength UV (VWD) detectors, and a quater-
nary solvent delivery system (Palo Alto, CA). A Sciex API
4000 mass spectrometer (Applied Biosystems, Foster City,
CA) coupled with HPLC was used for plasma drug analysis
and quantiﬁcation. Powder X-ray diffraction (PXRD) was
done on a Bruker D-8 Advance diffractometer for all the
solid-state works to conﬁrm no form changes. A scintilla-
tion counter was used for detection. In-house-fabricated
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(0.45 lm) pressed in the center and held in Bruker plastic
sample cup holders were utilized for all the analyses. The
water puriﬁcation system used was a Millipore milli-Q
system. All other chemicals were obtained from Aldrich
(St. Louis, MO) and were used without further puriﬁcation.
A ten stage cascade impactor purchased from California
Measurements (CA, USA) was used for aerosol particle
size measurement. PARI LC jet nebulizer (Wuppertal,
Germany) and BioAerosol Nebulizing Generator (BANG)
from CH technology (NJ, USA) were used in our study.
Jaeger-NYU Nose-Only Directed Flow Inhalation Expo-
sure System from CH technology (NJ, USA) was used for
aerosol animal dosing via a nose cone.
Method
Formulation
A bench scale wet milling (micronization) device was used
[23] with an appropriate amount of glass beads to produce
a nanosuspension formulation of ﬂuticasone. Tween 80 at
0.5% (w/w) in phosphate buffered saline (pH 7.4) was
added in a scintillation vial, and the mixture was stirred at
1,200 rpm for a period of 24 h with occasional shaking.
The stock formulation was then harvested and potency was
assessed by HPLC/DAD, and solid state checked by
Powder X-ray diffraction (PXRD). Thermal gravimetric
analysis with simultaneous differential thermal analysis
(TGA/SDTA) was done on a Mettler TGA/SDTA851e.
Particle size distribution was determined on a Beckman
Coulter LS 230 particle size analyzer using the small vol-
ume accessory (Miami, FL). A PIDS obscuration water
optical model was employed. Particle size distribution was
computed by the software using Mie scattering theory. The
large particle size (D50 = 1.6 and D90 = 2.9 lm) ﬂuti-
casone for in vivo comparison work was purchased from
Sequoia Research Products. The formulation was made by
directly suspending the bulk drug in 0.5% (w/w) Tween 80
in PBS. Potency, homogeneity, chemical stability, and
solid-state stability were performed following the same
procedure as listed above.
Aerosol particle size measurement
For the particle size distribution study, a ten-stage cascade
impactor (GSI, California Measurement, Sierra Madre,
CA., USA) was interposed between the nebulizer and the
pump. The aerosol was generated using dry air at 50 psi.
The impactor sampled the aerosol particles with aerody-
namic diameters of 8.0 and 0.125 lm at a continuous ﬂow
rate of 1 L/min
-1. After a predetermined duration, the
impactor was dismounted and different stages of the
cascade impactor were accurately weighted to determine
the amount of deposition. The mass median aerodynamic
diameter (MMAD) was calculated according to the percent
cumulative accumulation at each stage.
In Vivo and Sample Analysis
The Pﬁzer Institutional Animal Care and Use Committee
(IACUC) reviewed and approved the animal use in these
studies.TheAssociationforAssessmentandAccreditationof
Laboratory Animal Care, International fully accredits the
Pﬁzer animal care and use program. Male Balb/c mice
[8–10 weeks, *20 g] were used for all studies. For both the
intratracheal(IT)andintranasal(IN)groups,theanimalswere
anesthetized with an IP injection of a Ketamine/Xylazine
mixturepriortotheadministrationof1 mg/KgofFluticasone
in a nanosuspension and regular suspension. In the IT group,
the anesthetized animals were held vertically with their
mouths open. The tongue was pulled out gently to expose the
trachea. Twenty-ﬁve microliters of the dose solution was
pipetted into the trachea. For the IN group, the anesthetized
animals were held vertically, and 25 lL of the dose solution
was pipetted dropwise to the naris until it was completely
inhaled. For the aerosol dosing arm, the conscious animals
wereexposedtotheaerosolinanose-onlysystemfor10 min.
The animals were sacriﬁced with an IP injection of an over-
doseofKetamine/Xylazineimmediatelyafterdosing.Ablood
sample was collected through cardiac puncture.
Plasma samples were obtained by centrifugation at
8,000 rpm for 10 min, and 50 lL of the plasma sample was
extracted with 100 lL of acetonitrile containing 0.05 lM
of the internal standard (prepared in house). Samples were
allowed to settle, and 50 lL was transferred to a 96-well
plate. Analytical standards were prepared by spiking
known amount of standards into control plasma and
according to the above extraction procedure.
Whole lung samples were collected, weighed, and kept
on ice. In general, 200 mg of lung samples were ground in
diluent containing 70% ACN and 30% water with the
addition of 0.05 lM of internal standard (made in house) to
a ﬁnal volume of 3.0 mL. Samples were allowed to settle,
and 50 lL was transferred to a 96-well plate. Analytical
standards were prepared by spiking known amounts of
standards into blank lung tissue according to the above
extraction procedure. The concentration of ﬂuticasone in
all the samples was determined by LC/MS/MS on a Sciex
API 4000 mass spectrometer in positive electrospray mode
and MRM transition (m/z 502.1/313.7). Limit of detection
(LOD) was 0.00015 lg/mL, and limit of quantiﬁcation
(LOQ) was 0.0006 lg/mL.
Compatibility of regular and nanosuspension of ﬂuticasone
for aerosol delivery These experiments were conducted
256 Nanoscale Res Lett (2009) 4:254–261
123to determine the dose-dependent delivery to the lungs.
Different concentrations of the ﬂuticasone nanosuspension
were nebulized. Conscious mice were loaded into
restraining tubes, which left their naris exposed. The tubes
were then attached to a Jaeger-NYU Nose-Only Directed
Flow Inhalation Exposure System (12 port) via the nose
cone, so that the naris of the animals were directly in front
of a designated delivery vent. The dosing duration for
animals in all aerosol delivery groups was kept to 10 min
and sacriﬁced according to the general in vivo procedure.
Comparison of the efﬁciency of different dosing tech-
niques For comparison studies, the efﬁciency of two
nebulizers, PARI LC and BANG, was compared.
Unanesthetized mice were loaded into restraining tubes,
which left their naris exposed. The tubes were then
attached to a Jaeger-NYU Nose-Only Directed Flow
Inhalation Exposure System (12 port) via the nose cone,
so that the naris of the animals were directly in front of a
designated delivery vent. The ﬂow rate, duration of dos-
ing, dose solution concentration were optimized and
adjusted according to the dosage required. The dosing
duration for animals in all aerosol delivery groups was
kept to 10 min and sacriﬁced according to the general
in vivo procedure.
Results and Discussion
Micronization of ﬂuticasone successfully reduced the par-
ticle size of the bulk material from a mean value (D50) of 1.6
to 0.2 lm. The solid form of the micronized material was
examined by PXRD and TGA/SDTA, and demonstrated no
discernable change in the crystal form post the microniza-
tion process. (Fig. 1). Content uniformity, potency, and
homogeneity of the formulations were tested to ensure
quality of test material for all studies. In general, nanosus-
pension performs very well in all the tests. Both nano and
regular materials were dosed as suspension in vivo. Control
samples (milled vehicle) were very clean with no glass
shards observed. The dissolution rate was increased
by reducing the particle size and was calculated by the
Noye–Whitney equation. Solubility impact was calculated
by the Oswald–Freundlich equation (Log(Cs/C?) = 2aV/
(2.303RTqm) to further characterize the nanosuspension
[24]. For ﬂuticasone, a slight increase of solubility was
observed (from 0.7 lM to 1.1 lM) when particle size was
reducedto0.2 lm.Despitetheincreaseofsolubility,greater
than 99.9% ﬂuticasone still exists as solid crystalline
in nanosuspension. Thus, any particles formed from the
supernatant during nebulization were ignored. Only aerosol
particle from nanoparticle aggregation were considered.
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Fig. 1 Fluticasone PXRD patterns. Top is the post milling and bottom is the pre-milling API
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123The ﬁrst in vivo experiment was designed to compare
different dosing techniques and impact of the nanosus-
pension on lung deposition and systemic exposure. The
target was focused on higher and dose depended lung
disposition (to enhance local efﬁcacy) with lower systemic
exposure (reduce systemic side effect). For this experi-
ment, settings recommended by the manufacturer were
used to test both PARI LC and BANG nebulizers. It was
found that the PARI LC is more efﬁcient at a higher drug
concentration with the lung deposition of 2.4 and 14.9 lg
(approximately six folds) for the 1- and 5-mg/kg doses,
respectively. The plasma exposures correspond to lung
depositions with the evidence of reduced systemic expo-
sures. For the PARI LC nebulizer, plasma concentration
increase was observed when dose increased (for the 1- and
5-mg/kg doses: 0.01 and 0.02 lg/mL). However, the
degree of increase is much smaller (only two folds) when
compared with the lung exposure increase (approximately
six folds). The dose-dependent increase in lung exposure
along with lower systemic exposure was very much in
accordance with the desired outcome. In comparison, the
BANG devise lost efﬁciency at a higher dose with a
deposition of 2.0 and 0.3 lg for the 1- and 5-mg/kg doses,
respectively. The lack of delivery consistency at higher
dose for BANG devise was reﬂected in plasma level as
well. For the 1-mg/kg dose the plasma concentration was
determined at 0.01 lg/mL and for the 5-mg/kg dose,
plasma level was below the limit of detection. Based on the
data, PARI LC nebulizer was chosen for further studies.
The PARI LC devise, provided a dose-dependent drug
increase in lung disposition and evidence of reduced sys-
temic exposure (compare with the IT dose). Detailed
information is illustrated in Figs. 2 and 3.
Particle size distribution of the aerosol was further
investigated by using a ten-stage cascade impactor with
PARI LC nebulizer. The obtained data was used to further
adjust the nebulizer to maximize the efﬁciency. Key
parameters such as formulation concentration and system
ﬂow rates were investigated and found to impact the aer-
osol particle size and nebulizer efﬁciency. The system was
optimized based on the best-obtained parameters. It was
found when the optimized system was used, dose formu-
lation, concentration, and ﬂow rate had minimal effect on
the aerosol particle size. The MMAD was obtained by
linearly ﬁtting the percent cumulative accumulation at each
stage vs particle diameter. The obtained linear equations
(y = ax ? b) were used to calculate the MMAD. In gen-
eral, the MMAD of our optimized delivery setting was
found to be about 3.7 ± 0.3 lm throughout a wide dose
range (Table 1). The particle size of the nanosuspension
formulation used for the studies is 0.2 lm (D50). A
MMAD of 3.7 ± 0.3 lm indicates that aerosol particles
are indeed aggregates and each aggregate contains from 17
to 20 nanoparticles. The obtained MMAD is well within
the respirable range of an aerosol. Furthermore, in this
study, the MMAD (\5 lm) of nanosuspension aerosol
system is comparable to that of conventional aerosol sys-
tem prepared from organic propellant [25, 26], which is
clinically proven. Therefore, the delivery efﬁciency of
nanosuspension is believed to be comparable to conven-
tional systems. It is a viable option for pre-clinical drug
delivery, and thus can provide a more suitable method for
human dose projection.
Several in vivo experiments were adopted. The ﬁrst
experiment was designed to evaluate if regular suspension
is suitable for in vivo aerosol delivery. The regular sus-
pension was produced by using larger particle ﬂuticasone
(particle size D50 to D90 1.6–2.9 lm). The particle size
range used in this study is within the range used for dry
powder inhaler. In general, when larger particles were used
for aerosol delivery, the ﬂuticasone level was below LOD
in both lung tissue and plasma. This ﬁnding was not a
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Fig. 2 Effect of dosing
technique on lung deposition
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123surprise. During the inhalation of an aerosolized drug,
assuming if all the drug particles travel at a constant
velocity, the large particles carry a higher momentum due
to its increased mass. The higher momentum makes it
difﬁcult for these particles to negotiate the sharp turns in
the anatomy of the nasal cavity and the transition to the
upper airway. Thus, these larger particles tend to impact
the inside of the nasal cavity or the back of the throat
[27–29]. On the other hand, the smaller particles can
change their trajectory with relatively increased ease, and
can reach the lower parts of the airways [30]. Inside the
deep lungs, the drug deposition is due to many factors
which include Brownian motion, sedimentation due to
gravity, and random impaction [31, 32]. Based on the
number of nanoparticles found in each aggregate post
nebulization, it is hypothesized that after nebulization,
resulting aggregates from regular size particles were too
large for inhalation. Due to the larger particle size used
(particle size D50 to D90 1.6–2.9 lm), an aggregate with
n[4 will result in a particle with D50[5 lm which is
considered too large for inhalation. When particles are
larger than 5 lm, majority of the particles are trapped in
the nasal cavity and upper airways, and only a small
percentage will actually reach the deep lung [33]. The
majority of the ﬂuticasone will then be deposited in the
oral/nasal cavity and then swallowed. Because ﬂuticasone
is known to have very low oral absorption, low plasma
exposure was expected. Based on the observation, it is
concluded that regular size ﬂuticasone suspension is not
suitable for aerosol delivery. No further studies were con-
ducted with regular size ﬂuticasone.
The robustness of the delivery system was further tested
in vivo. In this experiment, the impact of system ﬂow rate
on performance was further investigated. The ﬂow rates
tested for this study were 0, 2, and 5 L/min to cover the
extreme cases, and the dose was set at 1 mg/kg. In general,
our system was very robust. Using our delivery system, the
lung depositions were not statistically signiﬁcant, even
under the extreme challenge. At a ﬂow rate 0, 2, and
5 L/min, the lung depositions were 2.3, 1.1, and 2.4 lg/g,
respectively (Fig. 4). Furthermore, the plasma concentra-
tion was about 0.01 lg/mL for all the groups (Fig. 5). If IT
delivery is considered to be 100% on target delivery, the
lung exposure via aerosol delivery is approximately 30%.
In a clinical setting, the typical fraction delivered to lung is
believed to be between 10 and 40% [9]. The amount of
ﬂuticasone deposited in the lung via nanosuspension aer-
osol delivery falls within the clinical range with low
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Table 1 PARI LC Nebulizer MADD via Impactor for Nanosuspen-
sion on Different Dose Range
Formulation
Concentration
(mg/mL)
Duration
(min)
MMAD
(lm)
21.74 2.0 3.6
4.35 4.0 4.1
2.44 4.0 3.5
0.43 8.0 3.9
0.04 8.0 3.4
Average 3.7 ± 0.3
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123variability. This device provided a much better conﬁdence
in delivery in a relevant preclinical model in a range which
mimics human exposure. Another highly desired advantage
is reﬂected in the reduced systemic exposure. The systemic
exposure from nanosuspension aerosol delivery is
approximately 25% of the IT delivery. This low systemic
exposure can provide a potential tool to differentiate top-
ical (lung) vs systemic efﬁcacy and side effects. This
advantage is particularly important, because a major focus
of pulmonary drug development is to improve local
exposure/efﬁcacy and minimizing systemic exposure and
side effects. The lower systemic exposure observed via
nanosuspension aerosol delivery will help researchers fur-
ther explore the feasibility to differentiating topical (lung)
vs systemic efﬁcacy and side effects pre-clinically. Based
on the results from various tests, we concluded that the
aerosol delivery of ﬂuticasone nanosuspension is very
robust and well suited for pre-clinical pulmonary drug
delivery. These novel studies demonstrate that combining
nano-suspension and aerosol delivery is a valuable tool for
pre-clinical pulmonary drug delivery. The major advanta-
ges of this delivery system include the absence of a
propellant, ease of production, no solubility limit of the
compound, and simulation of actual exposure in humans.
Conclusion
In pulmonary drug discovery, the ability to evaluate new
drugs for efﬁcacy in animal model with quick turnaround
and conﬁdence of delivery is very important. In this study,
we pioneered the usage of nanosuspension aerosol delivery
in rodents, which is a system that is not limited by the sol-
ubility of the test compound. We have designed and
validated a nanosuspension aerosol system that successfully
delivers drug to the target (lung) in the pre-clinical animal
model. Our data conﬁrm that the system is suitable for pre-
clinical drug delivery, and results from multiple conditions
are highly repeatable and robust. These studies demonstrate
that nanosuspensions combined with aerosol delivery could
serve as a valuable tool for pulmonary drug discovery.
References
1. R. Dahl, Respir. Med. 100, 1307 (2006). doi:10.1016/j.rmed.
2005.11.020
2. B.J. Lipworth, Arch. Intern. Med. 159, 941 (1999). doi:10.1001/
archinte.159.9.941
3. N.A. Hanania, K.R. Chapman, S. Kesten, Am. J. Med. 98, 196
(1995). doi:10.1016/S0002-9343(99)80404-5
4. A. Cave, P. Arlett, E. Lee, Pharmacol. Ther. 83, 153 (1999). doi:
10.1016/S0163-7258(99)00019-4
5. F.T. Leone, J.E. Fish, S.J. Szeﬂer, S.L. West, Chest 124, 2329
(2003). doi:10.1378/chest.124.6.2329
6. H. Chrystyn, Int. J. Clin. Pract. 61, 1022 (2007). doi:10.1111/
j.1742-1241.2007.01382.x
7. L. Thorsson, K. Dahlstrom, S. Edsbacker, A. Kallen, J. Paulson,
J.E. Wiren, Br. J. Clin. Pharmacol. 43, 155 (1997). doi:
10.1046/j.1365-2125.1997.d01-1425.x
8. L. Thorsson, S. Edsbacker, A. Kallen, C.G. Lofdahl, Br. J.
Clin. Pharmacol. 52, 529 (2001). doi:10.1046/j.0306-5251.2001.
01493.x
9. H. Derendorf, G. Hochhaus, H. Mollmann, J. Aerosol. Med.
14(Suppl 1), S9 (2001). doi:10.1089/08942680150506295
10. D.R. Crockford, Drug Deliv. Technol. 2(2), 46 (2002)
11. K. Nikander, Eur. Respir. Res. 7, 385 (1997)
12. Y. Lai, P.C. Chiang, J.D. Blom, N. Li, K. Shevlin, T.G. Brayman,
Y. Hu, J.G. Selbo, L. Hu, Nanoscale Res. Lett. 3, 321 (2008). doi:
10.1007/s11671-008-9160-2
13. P. Chiang, J. Wahlstrom, J. Selbo, S. Zhou, S. Wene, L. Albin, C.
Warren, M. Smith, S. Roberds, S. Ghosh, L. Zhang, D.K. Pretzer,
J. Exp. Nanosic. 2, 239 (2007)
14. K. Sablon, Nanoscale. Res. Lett. 3, 265 (2008). doi:10.1007/
s11671-008-9145-1
15. S.H. Kang, H.S. Lee, J. Lee, S. Jeong, J. Choi, S.C. Lee, K.J.
Kim, J.H. Chang, Nanoscale Res. Lett. 3, 355 (2008). doi:
10.1007/s11671-008-9165-x
16. B. Saha, J. Bhattacharya, A. Mukherjee, A.K. Ghosh, C.R. San-
tra, A.K. Dasgupta, P. Karmakar, Nanoscale Res. Lett. 2, 614
(2007). doi:10.1007/s11671-007-9104-2
17. J. Berry, L.C. Kline, J.K. Sherwood, S. Chaudhry, L. Obenauer-
Kutner, J.L. Hart, J. Sequeira, Drug Dev. Ind. Pharm. 30, 705
(2004). doi:10.1081/DDC-120039213
18. W.H. Finlay, K.W. Stapleton, P. Zuberbuhler, J. Aerosol. Med.
11(Suppl 1), S65 (1998)
19. M. Plackeand, W. Zimlich, Drug. Deliv. Tech. 2(4), 42 (2002)
20. J.A. Byrne, S.S. Strautnieks, G. Mieli-Vergani, C.F. Higgins, K.J.
Linton, R.J. Thompson, Gastroenterology 123, 1649 (2002). doi:
10.1053/gast.2002.36591
21. M. Dahlback, S. Eirefelt, K. Backstrom, P. Larsson, L.O. Almer,
P. Wollmer, B. Jonson, J. Aerosol. Med. 15, 27 (2002). doi:
10.1089/08942680252908557
22. R.L. Sherwood, P.T. Thomas, C.Y. Kawanishi, J.D. Fenters,
Appl. Environ. Microbiol. 54, 1744 (1988)
23. R. J. Haskell, Laboratory scale milling process, International Patent
WO 02/45691 A2, Pharmacia and Upjohn Company, US, 2002
24. M.J. Grau, O. Kayser, R.H. Muller, Int. J. Pharm. 196, 155
(2000). doi:10.1016/S0378-5173(99)00411-1
25. M.L. Sommervilleand, A.J. Hickey, AAPS PharmSciTech. 4, E58
(2003). doi:10.1208/pt040219
26. P. Zanen, L.T. Go, J.W. Lammers, Int. J. Pharm. 107, 211 (1994).
doi:10.1016/0378-5173(94)90436-7
27. Y.S. Cheng, Aerosol. Sci. Tech. 37, 659 (2003)
28. T.R. Sosnowski, A. Moskal, L. Gradon, Ann. Occup. Hyg. 51,1 9
(2007). doi:10.1093/annhyg/mel072
29. C. Mitsakou, D. Mitrakos, P. Neofytou, C. Housiadas, J. Aerosol.
Med. 20, 519 (2007). doi:10.1089/jam.2007.0625
Effect of System Flow on Plasma Concentration
0.000
0.002
0.004
0.006
0.008
0.010
0.012
0.014
0.016
0.018
0.020
0 L / Min 2 L / Min 5 L / Min
System Flow
P
l
a
s
m
a
 
c
o
n
c
.
 
(
µ
g
 
/
 
m
L
)
Fig. 5 Effect of system ﬂow on plasma exposure (PARI LC)
260 Nanoscale Res Lett (2009) 4:254–261
12330. N. Nowak, P.P. Kakade, A.V. Annapragada, Ann. Biomed. Eng.
31, 374 (2003). doi:10.1114/1.1560632
31. C. Darquenne, M. Paiva, G.K. Prisk, J. Appl. Physiol. 89, 1787
(2000)
32. A. Tsuda, J.P. Butler, J.J. Fredberg, J. Appl. Physiol. 76, 2510
(1994)
33. S.P. Newman, H.K. Chan, J. Aerosol. Med. Pulm. Drug Deliv. 21,
77 (2008)
Nanoscale Res Lett (2009) 4:254–261 261
123